SMS Pharmaceuticals Ratios

SMS Pharmaceuticals Ltd Ratios

The SMS Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of SMS Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking SMS Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

SMS Pharmaceuticals Ltd (NSE: SMSPHARMA, BSE: 532815) is currently trading at ₹385.20, with a market capitalization of ₹35.98B. As a major player in the Health technology sector and Pharmaceuticals: major industry, SMS Pharmaceuticals Ltd remains a key stock for fundamental analysis using SMS Pharmaceuticals Ltd Ratios.

SMS Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The SMS Pharmaceuticals Ltd P/E ratio currently stands at 27.27, making it one of the most tracked metrics in SMS Pharmaceuticals Ltd Ratios.

Historically, the SMS Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 27.27
• 2023: 30.25
• 2022: 0
• 2021: 12.76
• 2020: 16.84

The decline in SMS Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The SMS Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.95.

Historical P/B trend:

• 2024: 2.95
• 2023: 2.81
• 2022: 1.06
• 2021: 1.69

SMS Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The SMS Pharmaceuticals Ltd P/S ratio currently stands at 2.42, an important part of SMS Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.42
• 2023: 2.13
• 2022: 0.94
• 2021: 1.54

The rising SMS Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

SMS Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The SMS Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 29.22.

Historical SMS Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 29.22
• 2023: 52.83
• 2022: 291.16
• 2021: 29.72
• 2020: 12.46

The declining SMS Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

SMS Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The SMS Pharmaceuticals Ltd EV currently stands at ₹21.55B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 21.55B
• 2023: 17.52B
• 2022: 7.36B
• 2021: 10.11B

SMS Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The SMS Pharmaceuticals Ltd EV/EBITDA ratio is currently 15.65, a key metric in SMS Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 15.65
• 2023: 15.25
• 2022: 13.76
• 2021: 9.09

Higher SMS Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

SMS Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The SMS Pharmaceuticals Ltd D/E ratio is currently 0.49, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.49
• 2023: 0.52
• 2022: 0.55
• 2021: 0.56

SMS Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The SMS Pharmaceuticals Ltd ROE currently stands at 11.76%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 11.76
• 2023: 10
• 2022: -1.52
• 2021: 14.13

SMS Pharmaceuticals Ltd maintains stable profitability levels.

SMS Pharmaceuticals Ltd Ratios Analysis Summary

The SMS Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether SMS Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking SMS Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.